Tag: officers

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.

CALGARY, Alberta, July 29, 2025 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, loss (gain) on investments and other assets, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards (IFRS) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release.

VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its board of directors has approved the grant of an aggregate of 540,000 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan.

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the securities of Replimune Group, Inc. (NASDAQ: REPL) (“Replimune” or the “Company”)

JACKSONVILLE, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers,” “Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the quarterly period ended June 30, 2025, and provided updated 2025 earnings guidance. For the three months ended June 30, 2025 and 2024, Net Income Attributable to Common Shareholders was $0.56 per diluted share, and $0.54 per diluted share, respectively.

Net income available to common stockholders of $5.5 million and $48.0 million for the three and six months ended June 30, 2025, respectively, or $0.09 and $0.79 per diluted share, respectively.

The 2025 interim financial report, including the interim management report and the condensed consolidated interim financial statements at 30 June 2025, is available on the company’s website www.clariane.com. The condensed interim consolidated financial statements were approved by the Board of Directors at its meeting on 29 July 2025 and were subject to a limited review by the Statutory Auditors. The condensed interim consolidated financial statements have been prepared in accordance with IAS 34. For comparison purposes, the following financial information is presented excluding the application of IFRS 16

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DoubleVerify Holdings, Inc. (NYSE: DV) breached their fiduciary duties to shareholders.